Denali Therapeutics, Inc. (DNLI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$19.72-5.92%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · DNLI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -28.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
DNLI — M&A activity — Termination of a Material Definitive Agreement
Dated 2026-04-03
Termination of a Material Definitive Agreement. On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company Limited (“Takeda”) of its decision to terminate the Collaboration Agreement (the “Agreement”), dated January 3, 2018, between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN). The decision was driven by strategic considerations and is not related to efficacy or safety data. The termination will become effective 6…
Why it matters: The larger LUMA study failed to meet its main goals. BEACON will test DNL151 in people with a known LRRK2 gene change.
Watch forBEACON reports biomarker and safety data in the first half of 2027. The data may show pathway engagement.
Also watch forBEACON shows no biomarker change, a safety concern, or a delay beyond the first half of 2027.
Why it matters: Q2 was the first full sales quarter, with $3.6M in revenue. Q3 results will test the launch pace.
Watch forQ3 AVLAYAH net product revenue is at least $10M and no more than $12M.
Also watch forQ3 AVLAYAH net product revenue is below $10M or above $12M.
Why it matters: DNL126 is being developed for a disease with no approved therapy. A filing would mark a key step toward review.
Watch forDenali starts the global Phase 3 study and submits the DNL126 BLA in 2027.
Also watch forThe Phase 3 start or BLA filing slips past 2027, or Denali reports a stop to the program.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$180 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $518 loss on $10,000 · 5.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,528 loss on $10,000 · 35.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.